While 63% of respondents who had switched to a biosimilar said that they had been consulted in some form prior to the transition, 37% said that they had not been consulted (despite the fact that National Health Service guidelines require the patient to be consulted about such a switch).
Last month, UK group The Patients Association released results of a survey and focus group that sought to understand patient needs in switching to biosimilars from reference products.
In September 2018, the association surveyed 262 patients, 208 of whom were taking a biologic drug. (Notably, the survey took place prior to the launch of biosimilar adalimumab products in the United Kingdom.) The online survey contained 17 questions and was distributed to the group’s social media channels and weekly email newsletter. The group also held a 7-member focus group in Birmingham, United Kingdom, in order to understand patients’ views about whether they are receiving appropriate support during a switch to a biosimilar.
Among the survey respondents, 60.54% had rheumatoid arthritis, 10.73% had Crohn disease, 4.60% had ulcerative colitis, 4.60% had psoriatic arthritis, 0.77% had psoriasis, and 0.77% had ankylosing spondylitis. An additional 18.01% had other diseases. In total 69 people—27% of the total number of respondents—had already switched to a biosimilar.
While 63% of respondents who had switched to a biosimilar said that they had been consulted in some form prior to the transition, 37% said that they had not been consulted (despite the fact that National Health Service guidelines require the patient to be consulted about such a switch).
In total, 9 patients said that they had been given a verbal explanation of the switch, while another 9 patients reported having received both written and verbal explanations plus consultations with providers. Seven patients received a verbal explanation only, while 5 received both written and verbal explanations. Nine patients reported that they were not given any explanation of the switch. Furthermore, 49 patients (60%) said they had not been given any training or homecare support for the switch.
In free-response answers to a question asking what information would be helpful in the case of a switch, 101 patients indicated that they would like reassurance that changing to a biosimilar would not negatively affect their current health, or that if there was a change in disease activity, they could switch back to the originator product.
In the focus group, patients who had already been switched exhibited a high level of awareness of biosimilars. However, they “reported a very poor experience,” according to the association’s report. The respondents cited lack of information, lack of choice, multiple switches because of a lack of drug stock, fear about the biosimilar’s supply related to the United Kingdom’s withdrawal from the European Union, and not being monitored during administration of the new product.
“From the concerns raised and the suggestions about need for better information, shared decision making, and collaborative working between patients and clinicians, it would seem helpful to co-produce a set of tools to assist patients in the journey they describe,” wrote the report’s authors. “The aim would be to better inform and empower patients to take control of their situation and be more equal partners in their treatment plan and choice of medication.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.